Excellent communication piece! First-class response to a no-class reporter. GO OMER!
nice response by Omeros, it wasnt needed, but they set the record staright and now AF looks like a complete moron, no wonder the street fired him.
Looks like Adam Fraudstein has been smoked out as Art Doyle once and for all
I really hope the worst is over. Too many shorts and too many pretend investors. I have never seen a company like this with the potential and pipeline OMER has. I will buy more when this dust settles.
Proud of the resilience of the longs. No caving into 2-bit hack short scammers like AF
Lesson from AD and AF utter failure posts - always do your own DD. Never trust any one analyst. Or tout. Or board spammer (yes that means you Great Day). Elemer - all of them have masters and hidden agendas. Who I trust? Me! Who put this thing together? Me!!
Very impressive day. Fought off another smear campaign. Not buying or selling, just holding a respectable amount I'm satisfied with...........Kel
Didn't know of AF's reputation for stock manipulating but liked what I've read so I picked up another 2500 at 19.75 this morning on the opening. 19,000 should be enough for me for a while unless another buying opponent The charts don't look good but if somehow we close higher, technicians that follow this will have an impressive buy signal. If not the stock might continue to drift or be susceptible to wide swings on thin interest. Eventually the fundamentals will take over so continue to be patient
BRAVO on the response!!!! We go higher
I'm gonna keep continue OMER even just for the fact that company publicly responds to all BS hit pieces by shorts. Of course company is not going to disclose ALL clinical data due to multiple reasons. As a shareholder I don't expect that to happen as well.
LOL -- weak hands scared out again
What really gets me , all that AH , AF had to do is go back8 days for the news release on IgA one year after ending OMS 721 treatment and see the published results. Also statements from clinical Doctors not Omeros employees. Adam should be investigated by the SEC!
Looks like the hit pieces from doyle aka adam fraudstein are not working anymore. They need a new spokesman
Me thinks Adam F. worked with or is Art Doyle...
Cheers to anyone who didn't sell today.
Omeros' average analyst Price Target is mid $30s...
Looks like Adam/Art failing again
Sad that AF can't even move the needle as much as that group of hacks at Doyle.
How the once temporarily somewhat powerful have fallen.
Omeros Responds to Statnews.com Story SEATTLE--(BUSINESS WIRE)-- Omeros Corporation(OMER) stated today that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies as having a short position in Omeros’ stock. Because of its ongoing legal action, including a number of steps aimed at unmasking the identity of the individual(s) responsible, Omeros(OMER) elected not to respond to queries from a writer for statnews.com who evidently had early access to and commented through Twitter on the initial “Art Doyle” false report before it was broadly made public.
While, for the reason stated above, Omeros(OMER) will not engage in a running dialogue with this writer, the company will respond this one time to correct some of the inaccuracies in yesterday’s statnews.com story. Correct information is and has been publicly available to any individual wishing to obtain accurate background material.
The Superior Court of Washington for King County determined there was a likelihood that Omeros(OMER) would prevail on its defamation claim against the “Art Doyle” entity(ies) and granted a motion for preliminary injunction requiring removal of the defamatory reports and prohibiting posting of further defamatory statements. As of June 30, 2017, 54 patients had been enrolled in OMS721 Phase 2 clinical trials. Since then, the enrollment number has continued to increase. Presentations of OMS721 clinical data at international scientific meetings span February 2017 through June 2017. These presentations are directed to respective groups of patients and are not intended to reflect total patient counts. In addition, like most biopharmaceutical companies, Omeros(OMER) does not routinely release all clinical data as they are generated. As noted in the company’s press release dated August 4, 2017, more than 150 subjects had been dosed with OMS721, and that number continues to increase. On March 16, 2017, Omeros(OMER) publicly announced that enrollment had opened for its Phase 3 clinical trial evaluating OMS721 in patients with atypical hemolytic uremic syndrome, or aHUS. In connection with this study and consistent with regulations governing clinicaltrials.gov postings, a clinicaltrials.gov filing was made by the company on April 17, 2017. This date, as recorded by the website administrators at the National Institutes of Health, is found on the clinicaltrials.gov summary for this Phase 3 trial. The estimated completion date of the aHUS Phase 3 clinical trial for approximately 80 patients is listed as 2020 on clinicaltrials.gov. The posting on clinicaltrials.gov also clearly states that an interim analysis will be conducted following treatment of approximately 40 patients for potential submission for regulatory approval. This is consistent with Omeros’ publicly available statements that, based on discussions with both FDA and the European Medicines Agency, the company received guidance from those regulatory bodies that 40 patients may be sufficient for accelerated approval in the U.S. and for full approval in Europe. As noted in the company’s press release in February 2014, subjects in Omeros’ Phase 1 trial were dosed subcutaneously at increasing dose levels, with both subcutaneous and intravenous administration resulting in sustained and high degrees of lectin pathway inhibition. Since then, several cohorts of subjects have been administered repeated subcutaneous doses of OMS721, yielding comprehensive pharmacokinetic/pharmacodynamic (PK/PD) data. Intravenous loading followed by subcutaneous maintenance dosing in the aHUS Phase 3 clinical trial is based on those comprehensive PK/PD data. According to the FDA medical review, Alexion similarly used pharmacokinetic modeling to determine the dosing regimen for eculizumab (Soliris®) in the aHUS indication. Omeros (OMER), for competitive reasons and consistent with common practice in the industry, has not released any PK/PD data. Following submission of a request for breakthrough therapy designation based on Phase 2 clinical data in patients with immunoglobulin A (IgA) nephropathy, Omeros(OMER) received notification of breakthrough designation for OMS721 in IgA nephropathy in a letter from FDA dated June 8, 2017. As publicly disclosed, the Phase 3 clinical trial in this program is planned to initiate later this year. Omeros accurately reports the status and results of its commercial, clinical and development programs and will continue its practice of providing updates when appropriate.
About Omeros’ MASP Programs
Omeros (OMER) controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial
I am shocked that the stock has dropped so much with only 3 million shares dilution. We be the rev estimates by quite a lot and now have a lot of cash on hand. Also positive news with the drugs. Amazes me we drop so much.